A Prospective Cohort Study of Hard‐to‐Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add‐on to Optimal Local Care
International Wound Journal · 2026
DOI: 10.1111/iwj.71057 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Wound Journal, 2026. Verfasst von Serge Ynesta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cicat-Occitanie, Hôpital La Colombière, Montpellier, France. Hauptthemen laut MEDLINE: Wound Healing, Diabetic Foot, Leg Ulcer. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: OTR3.
Abstract (Originalsprache)
ReGenerating Tissue Agents (RGTA, trade name CACIPLIQ20) contain a structural analogue of heparan sulfates (HSs) that promotes tissue regeneration in hard‐to‐heal chronic wounds resistant to the best standard of care for 6 months or longer. The MATHCOW study aimed to evaluate the real‐life performance and safety of RGTA administered in addition to optimal treatment in diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and leg ulcers with an ischemic component (arterial ulcers). The primary outcome measure was the rate of ulcer closure within the first 20 weeks of treatment. A total of 191 patients were recruited; 173 signed informed consent and constituted the intention‐to‐treat (ITT) analysis set. The per‐protocol (PP) population included 114 patients. The primary endpoint was 50 wound closures at 20 weeks in the ITT analysis (28.9%) and 46 wound closures in the PP analysis (40.4%). Closure rates varied according to ulcer type: 43.7% for VLUs, 46.2% for DFUs, and 14.6% for arterial ulcers. Other endpoints also improved, including clinician global impression, pain, and ulcer area. Adverse events were recorded in 4% of cases. This open‐label study confirms the performance and tolerability of RGTA in a population of patients with particularly hard‐to‐heal chronic ulcers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cicat-Occitanie, Hôpital La Colombière, Montpellier, France.
- OTR3, Paris, France.
ORCID-Profile: Marion Mourgues, Chloé Geri, Martin Inizan, Denis Barritault, Frédéric Sedel
Förderung
- OTR3
Zitieren
APA
Ynesta, S., Mourgues, M., Geri, C., Inizan, M., Barritault, D., Sedel, F., Kerihuel, J. C., & Téot, L. (2026). A Prospective Cohort Study of Hard‐to‐Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add‐on to Optimal Local Care. International Wound Journal. https://doi.org/10.1111/iwj.71057
Vancouver
Ynesta S, Mourgues M, Geri C, Inizan M, Barritault D, Sedel F, et al. A Prospective Cohort Study of Hard‐to‐Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add‐on to Optimal Local Care. International Wound Journal. 2026. doi:10.1111/iwj.71057
BibTeX
@article{Ynesta2026,
author = {Ynesta, Serge and Mourgues, Marion and Geri, Chloé and Inizan, Martin and Barritault, Denis and Sedel, Frédéric and Kerihuel, Jean-Charles and Téot, Luc},
title = {A Prospective Cohort Study of Hard‐to‐Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add‐on to Optimal Local Care},
journal = {International Wound Journal},
year = {2026},
doi = {10.1111/iwj.71057}
}
EUVIMED